Results 71 to 80 of about 1,258 (118)

Beyond 40 fluorescent probes for deep phenotyping of blood mononuclear cells, using spectral technology. [PDF]

Front Immunol
Schmutz S, Commere PH, Montcuquet N, Cumano A, Ait-Mansour C, Novault S, Hasan M.   +6 more
europepmc   +1 more source

Probiotics: multifunctional microorganisms for human health and biotechnological applications. [PDF]

Front Microbiol
Ali M, Srivastava A, Arora PK.
europepmc   +1 more source

Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir. [PDF]

J Virol
Pascoe RD, Kim Y, Rhodes A, Ong J, Tumpach C, Gubser C, Chang JJ, McMahon JH, Lewin SR, Rasmussen TA.   +9 more
europepmc   +1 more source

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

Lancet Microbe
Chanda C, Kibengo F, Mutua M, Ogada F, Muturi-Kioi V, Akis Yildirim BM, Amondi M, Baines A, Basajja V, Borthwick N, Bosire K, Chambula E, Chetty P, Chinyenze K, Chirro O, Crook A, De Bont J, Fernandez N, Ejou P, Farah B, Glaze M, Gombe B, Gumbe A, Hayes P, Itwi S, Juma S, Kabarambi A, Kabengele C, Kafeero P, Kakande A, Kanungi J, Kidega W, King D, Mahira R, Malogo R, Matsoso M, Michelo C, Moyo A, Mugaba S, Mugenya I, Muhumuza P, Mujadidi YF, Muriuki M, Musale V, Mutua G, Muwowo M, Mwale F, Mwangi I, Nakimbugwe M, Namuyanja A, Nduati E, Nielsen L, Nyange J, Oino G, Okech B, Omosa-Manyonyi G, Otieno D, Palmer S, Phiri H, Ramko K, Rutishauser RL, Sayeed E, Sajabi R, Serwanga J, G-T Wee E, Wenden C, Cicconi P, Fast P, Gilmour J, Jaoko W, Kaleebu P, Kilembe W, Kuipers H, Sanders EJ, Hanke T.   +74 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Start-ups, Killer Acquisitions and Merger Control

SSRN Electronic Journal, 2020
Start-up or nascent firms play a vital role in competitive markets, but traditionally, their relevance to merger control has been limited to providing evidence that a relevant market was likely to become increasingly competitive. Recent empirical work has shown that in some cases the acquisition of a nascent firm has triggered the loss of not only a ...
exaly   +3 more sources

Merger Policy and the Timing of Killer and Continuation Acquisitions

Journal of Public Economic Theory
ABSTRACT I study a dynamic game of innovation and takeover between an incumbent and a potential entrant where the entrant knows whether it has the resources to complete a project and compete, but the incumbent does not and can wait to learn about it.
Antonio Tesoriere
exaly   +2 more sources

KILLER ACQUISITIONS AND COMPETITION LAW: IS THERE A GAP AND HOW SHOULD IT BE FILLED

National Law School of India Review, 2022
In innovation-driven budding markets, there is a high likelihood of ‘killer acquisitions’. Killer acquisitions stifle potential competition where an established player eliminates an innovative new product or removes the potential competitor entirely in its nascent stage.
exaly   +2 more sources